Last reviewed · How we verify
Vemurafenib plus Cobimetinib (vemurafenib-plus-cobimetinib)
Vemurafenib and cobimetinib inhibit the BRAF and MEK enzymes, respectively, disrupting the MAPK signaling pathway to halt cancer cell growth.
At a glance
| Generic name | vemurafenib-plus-cobimetinib |
|---|---|
| Sponsor | Pfizer Inc. |
| Phase | Phase 2 |
Mechanism of action
Vemurafenib targets the BRAF protein, while cobimetinib inhibits MEK, both part of the MAPK pathway. Together, they block signals that promote tumor growth and survival.
Approved indications
Common side effects
- Diarrhoea
- Nausea
- Fatigue
- Anaemia
- Rash
- Arthralgia
- Decreased appetite
- DIARRHOEA
- Vomiting
- Pyrexia
- Constipation
- Abdominal pain
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vemurafenib plus Cobimetinib CI brief — competitive landscape report
- Vemurafenib plus Cobimetinib updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI